Stability of the exacerbation pattern defined by GOLD 2017 in a real-world COPD population

J. Fu (Chengdu, Sichuan, China)

Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Session: What is new in COPD diagnosis and classification?
Session type: Thematic Poster
Number: 3617
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Fu (Chengdu, Sichuan, China). Stability of the exacerbation pattern defined by GOLD 2017 in a real-world COPD population. 3617

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Distribution of COPD patients in the GOLD assessment framework by exacerbations
Source: Annual Congress 2012 - COPD epidemiology
Year: 2012

Implementation of the GOLD 2017 disease classification in a real-life COPD cohort
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018




Validation of the GOLD 2017 classification in predicting exacerbations and mortality in COPD patients
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017

Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016


Distribution of a COPD population based on the GOLD assessment framework
Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Year: 2012


Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013

Three year follow-up of distribution and stability of patients with COPD according GOLD 2014
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015


2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016


Prediction models for exacerbations in different COPD patient populations: Results of five large databases
Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD
Year: 2016

Prevalence and severity of GOLD defined COPD in adults
Source: Eur Respir J 2002; 20: Suppl. 38, 123s
Year: 2002

Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013

Influence of the seasons on exacerbation characteristics in a cohort of COPD patients (EXACO study)
Source: Annual Congress 2013 –Factors associated with outcomes in COPD
Year: 2013


Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013


The distribution of COPD in UK general practice using the 2017 GOLD classification
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017


Validation of the GOLD 2017 classification in a Chinese COPD cohort
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017


Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Frequency and severity of exacerbations reflect COPD severity, but not COPD phenotype as determined by quantitative CT
Source: International Congress 2014 – Markers
Year: 2014

GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018




Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019


Agreement of severity stages and exacerbations building the new COPD risk groups
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013